285 related articles for article (PubMed ID: 25015535)
1. Quetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MB; Bilenberg N; Stenstrøm AD; Pedersen J; Nyvang L; Madsen S; Lauritsen MB; Vernal DL; Thomsen PH; Paludan J; Werge TM; Winge K; Juul K; Gluud C; Skoog M; Wetterslev J; Jepsen JR; Correll CU; Fink-Jensen A; Fagerlund B
BMC Psychiatry; 2014 Jul; 14():199. PubMed ID: 25015535
[TBL] [Abstract][Full Text] [Related]
2. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
3. Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) Trial.
Jensen KG; Correll CU; Rudå D; Klauber DG; Decara MS; Fagerlund B; Jepsen JRM; Eriksson F; Fink-Jensen A; Pagsberg AK
J Am Acad Child Adolesc Psychiatry; 2019 Nov; 58(11):1062-1078. PubMed ID: 30858012
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.
Kane JM; Correll CU; Goff DC; Kirkpatrick B; Marder SR; Vester-Blokland E; Sun W; Carson WH; Pikalov A; Assunção-Talbott S
J Clin Psychiatry; 2009 Oct; 70(10):1348-57. PubMed ID: 19906340
[TBL] [Abstract][Full Text] [Related]
5. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
6. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study.
Shajahan P; Keith S; Majjiga C; Murphy J; MacRae A; Bashir M; Taylor M
J Clin Psychiatry; 2009 May; 70(5):692-8. PubMed ID: 19284930
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: a 12-week randomized, flexible-dose, open-label trial.
Crespo-Facorro B; Ortiz-García de la Foz V; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Vázquez-Barquero JL; Pérez-Iglesias R
Schizophr Res; 2013 Jul; 147(2-3):375-82. PubMed ID: 23643328
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
10. Early Antipsychotic Nonresponse as a Predictor of Nonresponse and Nonremission in Adolescents With Psychosis Treated With Aripiprazole or Quetiapine: Results From the TEA Trial.
Pagsberg AK; Krogmann A; Jeppesen P; von Hardenberg L; Klauber DG; Jensen KG; Rudå D; Decara MS; Jepsen JRM; Fagerlund B; Fink-Jensen A; Correll CU; Galling B
J Am Acad Child Adolesc Psychiatry; 2022 Aug; 61(8):997-1009. PubMed ID: 35026408
[TBL] [Abstract][Full Text] [Related]
11. Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.
Crespo-Facorro B; de la Foz VO; Mata I; Ayesa-Arriola R; Suarez-Pinilla P; Valdizan EM; Martinez-Garcia O; Pérez-Iglesias R
Psychopharmacology (Berl); 2014 Jan; 231(2):357-66. PubMed ID: 23958945
[TBL] [Abstract][Full Text] [Related]
12. Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.
Vázquez-Bourgon J; Pérez-Iglesias R; Ortiz-García de la Foz V; Suárez Pinilla P; Díaz Martínez Á; Crespo-Facorro B
Psychopharmacology (Berl); 2018 Jan; 235(1):245-255. PubMed ID: 29075885
[TBL] [Abstract][Full Text] [Related]
13. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).
Hanssens L; L'Italien G; Loze JY; Marcus RN; Pans M; Kerselaers W
BMC Psychiatry; 2008 Dec; 8():95. PubMed ID: 19102734
[TBL] [Abstract][Full Text] [Related]
14. Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trial.
Jensen KG; Gärtner S; Correll CU; Rudå D; Klauber DG; Stentebjerg-Olesen M; Fagerlund B; Jepsen JR; Fink-Jensen A; Juul K; Pagsberg AK
Psychopharmacology (Berl); 2018 Mar; 235(3):681-693. PubMed ID: 29185022
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison.
Crespo-Facorro B; Pérez-Iglesias R; Mata I; Ortiz-Garcia de la Foz V; Martínez-Garcia O; Valdizan EM; Vazquez-Barquero JL
J Clin Psychopharmacol; 2013 Apr; 33(2):215-20. PubMed ID: 23422371
[TBL] [Abstract][Full Text] [Related]
18. Treatment of psychosis: 30 years of progress.
De Oliveira IR; Juruena MF
J Clin Pharm Ther; 2006 Dec; 31(6):523-34. PubMed ID: 17176358
[TBL] [Abstract][Full Text] [Related]
19. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.
Pérez-Iglesias R; Ortiz-Garcia de la Foz V; Martínez García O; Amado JA; Garcia-Unzueta MT; Ayesa-Arriola R; Suarez-Pinilla P; Tabares-Seisdedos R; Crespo-Facorro B
Schizophr Res; 2014 Oct; 159(1):90-4. PubMed ID: 25151200
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
Mukundan A; Faulkner G; Cohn T; Remington G
Cochrane Database Syst Rev; 2010 Dec; (12):CD006629. PubMed ID: 21154372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
